

**Supplementary Table 2.** Incidence Rates (Unique Patients with Events Per 100 Patient-Years) for Hospitalized Infections in the JMDC and MDV Databases

Group	Hospitalized infection 1 <sup>a</sup>			Hospitalized infection 2 <sup>b</sup>		
	No.	PY	IR (95% CI)	No.	PY	IR (95% CI)
Group 1 (CS, IM, or TNFi)						
Male	156	9,200.83	1.70 (1.43–1.96)	141	9,233.08	1.53 (1.28–1.78)
Female	122	6,914.17	1.76 (1.45–2.08)	117	6,948.08	1.68 (1.38–1.99)
<35 yr	45	3,885.67	1.16 (0.82–1.50)	40	3,897.67	1.03 (0.71–1.34)
≥35 yr	233	12,229.33	1.91 (1.66–2.15)	218	12,283.50	1.78 (1.54–2.01)
<50 yr	88	8,820.83	1.00 (0.79–1.21)	76	8,850.92	0.86 (0.67–1.05)
≥50 yr	190	7,294.17	2.61 (2.23–2.98)	182	7,330.25	2.48 (2.12–2.84)
<65 yr	168	13,150.83	1.28 (1.08–1.47)	145	13,211.75	1.10 (0.92–1.28)
≥65 yr	110	2,964.17	3.71 (3.02–4.40)	113	2,969.42	3.81 (3.10–4.51)
Group 2 (IM)						
Male	61	4,949.42	1.23 (0.92–1.54)	57	4,960.33	1.15 (0.85–1.45)
Female	47	3,673.42	1.28 (0.91–1.65)	50	3,680.75	1.36 (0.98–1.74)
<35 yr	19	1,919.58	0.99 (0.55–1.44)	17	1,921.83	0.89 (0.46–1.31)
≥35 yr	89	6,703.25	1.33 (1.05–1.60)	90	6,719.25	1.34 (1.06–1.62)
<50 yr	32	4,554.25	0.70 (0.46–0.95)	26	4,566.83	0.57 (0.35–0.79)
≥50 yr	76	4,068.58	1.87 (1.45–2.29)	81	4,074.25	1.99 (1.56–2.42)
<65 yr	63	7,083.42	0.89 (0.67–1.11)	55	7,108.75	0.77 (0.57–0.98)
≥65 yr	45	1,539.42	2.92 (2.07–3.78)	52	1,532.33	3.39 (2.47–4.32)
Group 2-1 (TAC or CyA)						
Male	8	138.58	5.77 (1.77–9.77)	9	134.83	6.68 (2.31–11.04)
Female	11	261.33	4.21 (1.72–6.70)	14	260.58	5.37 (2.56–8.19)
<35 yr	1	49.50	2.02 (0.00–5.98)	0	50.83	0.00 (0.00–0.00)
≥35 yr	18	350.42	5.14 (2.76–7.51)	23	344.58	6.68 (3.95–9.40)
<50 yr	4	145.50	2.75 (0.06–5.44)	4	145.17	2.76 (0.06–5.46)
≥50 yr	15	254.42	5.90 (2.91–8.88)	19	250.25	7.59 (4.18–11.01)
<65 yr	7	249.08	2.81 (0.73–4.89)	9	244.17	3.69 (1.28–6.09)
≥65 yr	12	150.83	7.96 (3.45–12.46)	14	151.25	9.26 (4.41–14.11)
Group 2-2 (6-MP or AZA)						
Male	53	4,810.83	1.10 (0.81–1.40)	48	4,825.50	1.00 (0.71–1.28)
Female	36	3,412.08	1.06 (0.71–1.40)	36	3,420.17	1.05 (0.71–1.40)
<35 yr	18	1,870.08	0.96 (0.52–1.41)	17	1,871.00	0.91 (0.48–1.34)
≥35 yr	71	6,352.83	1.12 (0.86–1.38)	67	6,374.67	1.05 (0.80–1.30)
<50 yr	28	4,408.75	0.64 (0.40–0.87)	22	4,421.67	0.50 (0.29–0.71)
≥50 yr	61	3,814.17	1.60 (1.20–2.00)	62	3,824.00	1.62 (1.22–2.03)
<65 yr	56	6,834.33	0.82 (0.61–1.03)	46	6,864.58	0.67 (0.48–0.86)
≥65 yr	33	1,388.58	2.38 (1.57–3.19)	38	1,381.08	2.75 (1.88–3.63)

(Continued to the next page)

Supplementary Table 2. Continued

Group	Hospitalized infection 1 <sup>a</sup>			Hospitalized infection 2 <sup>b</sup>		
	No.	PY	IR (95% CI)	No.	PY	IR (95% CI)
Group 3 (TNFi)						
Male	13	1,226.25	1.06 (0.48–1.64)	12	1,227.58	0.98 (0.42–1.53)
Female	19	1,187.08	1.60 (0.88–2.32)	16	1,194.42	1.34 (0.68–2.00)
<35 yr	5	656.00	0.76 (0.09–1.43)	4	657.00	0.61 (0.01–1.21)
≥35 yr	27	1,757.33	1.54 (0.96–2.12)	24	1,765.00	1.36 (0.82–1.90)
<50 yr	14	1,432.92	0.98 (0.47–1.49)	11	1,440.75	0.76 (0.31–1.22)
≥50 yr	18	980.42	1.84 (0.99–2.68)	17	981.25	1.73 (0.91–2.56)
<65 yr	24	1,984.33	1.21 (0.73–1.69)	19	1,994.00	0.95 (0.52–1.38)
≥65 yr	8	429.00	1.87 (0.57–3.16)	9	428.00	2.10 (0.73–3.48)
Group 4 (IM and TNFi)						
Male	14	1,508.08	0.93 (0.44–1.42)	16	1,508.67	1.06 (0.54–1.58)
Female	4	745.75	0.54 (0.01–1.06)	4	746.17	0.54 (0.01–1.06)
<35 yr	6	620.42	0.97 (0.19–1.74)	6	620.42	0.97 (0.19–1.74)
≥35 yr	12	1,633.42	0.74 (0.32–1.15)	14	1,634.42	0.86 (0.41–1.31)
<50 yr	9	1,391.75	0.65 (0.22–1.07)	12	1,390.17	0.86 (0.38–1.35)
≥50 yr	9	862.08	1.04 (0.36–1.73)	8	864.67	0.93 (0.28–1.57)
<65 yr	13	1,968.58	0.66 (0.30–1.02)	14	1,969.08	0.71 (0.34–1.08)
≥65 yr	5	285.25	1.75 (0.22–3.29)	6	285.75	2.10 (0.42–3.78)

<sup>a</sup>Hospitalized infection 1 was defined as an infection which results in hospitalization.

<sup>b</sup>Hospitalized infection 2 was defined as an infection which results in the most charged medical resources during hospitalization.

JMDC, Japan Medical Data Center; MDV, Medical Data Vision; PY, patient-years; IR, incidence rate (unique patients with events per 100 PY); CI, confidence interval; CS, corticosteroid; IM, immunosuppressant; TNFi, tumor necrosis factor inhibitor; TAC, tacrolimus; CyA, cyclosporine; 6-MP, 6-mercaptopurine; AZA, azathioprine.